Wall Street brokerages forecast that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will post ($0.53) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Cellular Biomedicine Group’s earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.50). Cellular Biomedicine Group also reported earnings per share of ($0.53) in the same quarter last year. The business is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that Cellular Biomedicine Group will report full year earnings of ($2.08) per share for the current year, with EPS estimates ranging from ($2.28) to ($1.90). For the next financial year, analysts anticipate that the business will post earnings of ($2.01) per share, with EPS estimates ranging from ($2.05) to ($1.97). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Cellular Biomedicine Group.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported ($0.51) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. The company had revenue of $0.05 million during the quarter. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%.
A number of research firms have recently issued reports on CBMG. BidaskClub upgraded Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald began coverage on Cellular Biomedicine Group in a research note on Tuesday, June 25th. They issued an “overweight” rating and a $27.00 target price for the company. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $27.50.
Several hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA grew its stake in shares of Cellular Biomedicine Group by 1,641.8% in the first quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 2,315 shares in the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Cellular Biomedicine Group in the fourth quarter valued at about $81,000. Rhumbline Advisers grew its stake in shares of Cellular Biomedicine Group by 49.2% in the fourth quarter. Rhumbline Advisers now owns 15,377 shares of the biotechnology company’s stock valued at $272,000 after buying an additional 5,074 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Cellular Biomedicine Group by 16.3% in the fourth quarter. Bank of New York Mellon Corp now owns 37,857 shares of the biotechnology company’s stock valued at $669,000 after buying an additional 5,308 shares in the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Cellular Biomedicine Group in the fourth quarter valued at about $110,000. Institutional investors and hedge funds own 18.99% of the company’s stock.
NASDAQ:CBMG traded up $1.42 on Friday, hitting $16.53. 162,879 shares of the stock were exchanged, compared to its average volume of 34,739. The stock has a market capitalization of $299.03 million, a PE ratio of -8.10 and a beta of 2.70. The business has a fifty day moving average of $15.82. Cellular Biomedicine Group has a fifty-two week low of $12.04 and a fifty-two week high of $25.00.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Further Reading: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.